Merck KGAA/Pfizer Discontinue Phase III Avelumab/Talazoparib Combo Study In Ovarian Cancer

 
• By John Davis

The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the big pharma alliance ending the Phase III JAVELIN Ovarian PARP 100 study.  

Stop
Competitive Pressures Can Lead To A Rethink of Development Strategies • Source: Shutterstock

More from Immuno-oncology

More from Anticancer